My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.78 -0.36 (-0.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

33 34 35 36 37 38 39 40 Next >

Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis ↗

February 10, 2022

The

Via Benzinga

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗

February 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Markets News for Tuesday ↗

February 08, 2022

Oil stocks are up on huge gains.

Via Talk Markets

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More ↗

February 06, 2022

Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...

Via Talk Markets

Sanofi: Q4 Earnings Insights ↗

February 04, 2022

Sanofi (NASDAQ:SNY) reported its Q4 earnings results on Friday, February 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Sanofi SA: An Expected Move Towards The $52.90 ↗

February 04, 2022

Today we can expect a move towards the $52.90 resistance, possibly further into the $54 price range, anticipating positive news.

Via Talk Markets

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures ↗

February 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use ↗

January 28, 2022

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

Via Benzinga

Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars ↗

February 04, 2022

Sanofi SA's (NASDAQ: SNY)

Via Benzinga

Earnings Scheduled For February 4, 2022 ↗

February 04, 2022

Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter.

Via Benzinga

A Preview Of Sanofi's Earnings ↗

February 03, 2022

Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will likely...

Via Benzinga

Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028

February 03, 2022

Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,...

Via FinancialNewsMedia

Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics ↗

February 02, 2022

Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates ↗

February 01, 2022

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.

Via Benzinga

5 Things To Expect This Week ↗

January 31, 2022

While the "January effect" was rather disappointing, February kicks off with an important week ahead for many types of investors.

Via InvestorPlace

The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗

January 31, 2022

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Via Benzinga

CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation ↗

January 31, 2022

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a posi

Via Benzinga

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron ↗

January 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential

January 24, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at...

Via FinancialNewsMedia

Why Jim Cramer Like NextEra Energy And Lincoln Electric? ↗

January 21, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said NextEra Energy, Inc. (NYSE:

Via Benzinga

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease ↗

January 19, 2022

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in...

Via Benzinga

Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares ↗

January 13, 2022

Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma...

Via Benzinga

Acasti Pharma: Bouncing Back With a New Drug Pipeline ↗

January 04, 2022

Picture credit: Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028

January 04, 2022

Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,...

Via FinancialNewsMedia

Sanofi Expects Q4 FY21 Vaccine Sales Lower Than Year-Ago, Positive Currency Impact ↗

January 04, 2022

Sanofi SA (NASDAQ: SNY) says the preliminary estimate of currency impact on Q4 sales and business EPS is approximately +1.5% and +2.5%. Also, the Company expects...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗

December 31, 2021

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...

Via Benzinga

3 Cathie Wood Stocks To Buy On The Dip ↗

December 25, 2021

Institutional investor Cathie Wood gained popularity after her ETFs generated big gains last year. Wood asserted recently that her stocks are poised for long-term gains. Hence, we think investing in...

Via Talk Markets

Plague Year Reversal ↗

December 21, 2021

Just in time for Christmas, the market decided to go up today pretty much across the board.

Via Talk Markets

The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗

December 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...

Via Benzinga

< Previous 1 2

...

33 34 35 36 37 38 39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.